Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of neoadjuvant chemoradiotherapy followed by atezolizumab with or without tiragolumab in locally advanced rectal cancer
CTR20211659Phase 2Active
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and tiragolumab in rectal adenocarcinoma (2 arms), sponsored by Roche. Primary endpoint: Pathological complete response rate. Started Mar 2022; status: active.
02
Drugs
atezolizumabtiragolumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on CTR20211659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211659.